马依彤,谢翔

• 1:新疆医科大学第一附属医院心脏中心

摘要(Abstract)：

<正>急性冠状动脉综合征(acute coronary syndrome,ACS)是一种非常常见的冠状动脉粥样硬化性心脏病急性发作临床类型,包括ST段抬高ACS和非ST段抬高ACS,主要发病机制是斑块破裂继发血栓形成,从而导致心肌缺血缺氧或者发生坏死。因此,在ACS的治疗中,除了再灌注治疗外,抗栓药物治疗也发挥着重要的作用。目前的抗栓药物主要有两大类,抗血小板类药物和抗凝血酶类药物。抗血小板药物主要包括阿司匹林、噻吩并吡啶类衍生物和血小板蛋白(GPI)Ⅱb/Ⅲa拮抗剂等;抗凝血酶类药物主要包括肝素、低分子肝素和维生素K拮抗剂等。另外,又

关键词(KeyWords)： 急性冠状动脉综合征;抗血小板治疗

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金资助项目(81160017)

作者(Author): 马依彤,谢翔

参考文献(References)：

• [1]Jonas DE,Wines R.Pharmacogenomic testing and the prospect of individualized treatment.N C Med J,2013,74:485-493.
• [2]Melloni C,Jones WS,Washam JB,et al.Antiplatelet and Anticoagulant Treatments for Unstable Angina/Non–ST Elevation Myocardial Infarction[Internet].Rockville(MD):Agency for Healthcare Research and Quality(US),2013 Nov.
• [3]Damman P,Varenhorst C,Koul S,et al.Treatment Patterns and Outcomes in Patients Undergoing Percutaneous Coronary Intervention Treated With Prasugrel or Clopidogrel(from the Swedish Coronary Angiography and Angioplasty Registry[SCAAR]).Am J Cardiol,2014,113:64-69.
• [4]Angiolillo DJ,Ferreiro JL,Price MJ,et al.Platelet function and genetic testing.J Am Coll Cardiol,2013,62:S21-S31.
• [5]Bonello L,Camoin-Jau L,Arques S,et al.Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance:a multicenter randomized prospective study.J Am Coll Cardiol,2008,51:1404-1411.
• [6]Valgimigli M,Campo G,de Cesare N,et al.Intensifying platelet inhibition with tirofi ban in poor responders to aspirin,clopidogrel,or both agents undergoing elective coronary intervention:results from the double-blind,prospective,randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.Circulation,2009,119:3215-3222.
• [7]Levine GN,Bates ER,Blankenship JC,et al.2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention.A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.J Am Coll Cardiol,2011,58:e44-e122.
• [8]Wright RS,Anderson JL,Adams CD,et al.2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction(Updating the 2007 Guideline):a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Circulation,2011,123:2022-2060.
• [9]Hamm CW,Bassand JP,Agewall S,et al.ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:The Task Force for the management of acute coronary syndromes(ACS)in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC).Eur Heart J,2011,32:2999-3054.
• [10]Wang X,Han A,Wen C,et al.The Effects of H2S on the Activities of CYP2B6,CYP2D6,CYP3A4,CYP2C19 and CYP2C9 in Vivo in Rat.Int J Mol Sci,2013,14:24055-24063.
• [11]Kanaji T,Okamura T,Osaki K,et al.A common genetic polymorphism(46 C to T substitution)in the 5'2 untranslated region of the coagulation factorⅩⅡgene is associated with low translation effi ciency and decrease in plasma factorⅩⅡlevel.Blood,1998,91:2010-2014.
• [12]Suzuki K,Henke J,IwataM,et al.Novel polymorphisms and haplotypes in the human coagulation factorⅩⅢA-subunit gene.Hum Genet,1996,98:393-395.
• [13]Kohler HP,Stickland MH,Ossei-GerningN,et al.Association of a common polymorphism in the factorⅩⅢgene with myocardial infarction.Thromb Haemost,1998,79:8-13.
• [14]Suh JW,Koo BK,Zhang SY,et al.Increased risk of atherothrombotic events associated withcytochrome P450 3A5 polymorphism in patients taking clopidogrel.CMAJ,2006,174:1715-1722.
• [15]Smith SM,Judge HM,Peters G,et al.Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.Platelets.2006;17(4):250-8.
• [16]Turgeon J,Pharand C,Michaud V.Understanding clopidogrel effi cacy in the presence of cytochrome P450 polymorphism.CMAJ,2006,174:1729
• [17]Xie X,Ma YT,Yang YN,et al.Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention:a randomized control trial.Int J Cardiol,2013,168:3736-3740.